Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
Article
Sulman, Erik P, Won, Minhee, Blumenthal, Deborah T et al. (2013). Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
. JOURNAL OF CLINICAL ONCOLOGY, 31(15_suppl), lba2010-lba2010. 10.1200/jco.2013.31.15_suppl.lba2010
Sulman, Erik P, Won, Minhee, Blumenthal, Deborah T et al. (2013). Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
. JOURNAL OF CLINICAL ONCOLOGY, 31(15_suppl), lba2010-lba2010. 10.1200/jco.2013.31.15_suppl.lba2010